<DOC>
	<DOCNO>NCT02783573</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy study drug know LY3314814 participant mild Alzheimer 's disease ( AD ) dementia .</brief_summary>
	<brief_title>A Study LY3314814 Participants With Mild Alzheimer 's Disease Dementia</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>Participant must meet National Institute Aging ( NIA ) Alzheimer 's Association ( AA ) ( NIAAA ) criteria probable AD dementia . MMSE score 20 26 inclusive screen visit . For diagnosis mild AD dementia , participant must CDR global score 0.5 1 , memory box score â‰¥0.5 screening . Evidence amyloid pathology . The participant must reliable study partner he/she cohabits regular contact . Significant and/or current neurological disease affect central nervous system , AD , may affect cognition ability complete study , include limited , dementias , repetitive head trauma , serious infection brain , Parkinson 's disease , epilepsy , cervicocranial vascular disease . Participants current primary psychiatric diagnosis AD , judgment investigator , psychiatric disorder symptom likely confound interpretation drug effect , affect cognitive assessment , affect participant 's ability complete study . Participants history schizophrenia chronic psychosis exclude . Within 1 year screen visit screen randomization , follow : myocardial infarction ; moderate severe congestive heart failure , New York Heart Association class III IV ; hospitalization , symptom , unstable angina ; syncope due orthostatic hypotension unexplained syncope ; know significant structural heart disease ( , significant valvular disease , hypertrophic cardiomyopathy ) ; hospitalization arrhythmia . Congenital QT prolongation . Intermittent second thirddegree atrioventricular ( AV ) heart block AV dissociation history ventricular tachycardia . A correct QT ( QTcF ) interval measurement &gt; 470 millisecond ( men woman ) screening ( determined investigational site ) . History malignant cancer within last 5 year . History vitiligo and/or current evidence postinflammatory hypopigmentation . Calculated creatinine clearance &lt; 30 milliliter per minute ( CockcroftGault formula ; Cockcroft Gault 1976 ) screen . Currently enrol clinical trial involve investigational product type medical research judge scientifically medically compatible study .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>dementia</keyword>
	<keyword>brain disease</keyword>
	<keyword>neurodegenerative disease</keyword>
	<keyword>central nervous system disease</keyword>
	<keyword>nervous system disease</keyword>
	<keyword>mental disorder</keyword>
	<keyword>delirium , dementia , amnestic , cognitive</keyword>
	<keyword>tauopathies</keyword>
	<keyword>memory</keyword>
	<keyword>amyloid</keyword>
</DOC>